Physician profile
Alan Kutner
NPI 1265438386
$3,530.15
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $217 · 2021: $1,056 · 2022: $1,116 · 2023: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $857.68 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $441.64 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.91 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $297.12 | 2019-2022 | |
| Astellas Pharma US INC | $241.26 | 2019-2022 | |
| Abbvie INC. | $226.49 | 2019-2023 | |
| Pfizer INC. | $126.17 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $117.41 | 2022 | |
| Amarin Pharma, INC. | $102.78 | 2020-2022 | |
| Amgen INC. | $100.38 | 2019-2022 | |
| Allergan, INC. | $69.88 | 2019 | |
| Gilead Sciences, INC. | $69.47 | 2021 | |
| Lilly USA, LLC | $68.59 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.64 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $47.35 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $41.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $40.28 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $34.72 | 2019 | |
| Shire North American Group INC | $32.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.94 | 2021 | |
| Amneal Pharmaceuticals LLC | $30.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $28.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.64 | 2021 | |
| Redhill Biopharma INC. | $18.82 | 2020 | |
| Horizon Therapeutics Plc | $18.73 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.00 | 2021 | |
| Currax Pharmaceuticals LLC | $17.45 | 2021 | |
| Sanofi Pasteur INC. | $16.40 | 2020 | |
| Celgene Corporation | $15.98 | 2021 | |
| Eisai INC. | $15.91 | 2021 | |
| Qol Medical, LLC | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kutner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.